April 10, 2026 — Two back-to-back regulatory developments from China's National Medical Products Administration (NMPA) are reshaping the global biologics manufacturing landscape — and creating immediate commercial opportunities for API intermediates suppliers, bioprocessing equipment manufacturers, and contract development and manufacturing organizations (CDMOs) worldwide.
On April 8, Altruist Biologics — a wholly owned subsidiary of Innovent Biologics — secured the first-ever Drug Product Manufacturing License (C Certificate) for a 20,000-liter scale biologics facility in China. Just six days earlier, on April 2, the NMPA issued a formal notice rolling out biologics segmented manufacturing nationwide, effectively ending the long-standing "one-site, one-process" requirement that had constrained China's biologics supply chain flexibility.
Together, these developments signal that China's biologics manufacturing ecosystem is entering a new phase of scale, regulatory maturity, and global integration — with significant implications for upstream suppliers.
Altruist Biologics' Hangzhou facility now holds the distinction of being the first biologics plant in China to receive commercial manufacturing certification at the 20,000-liter bioreactor scale. The site currently operates four 20,000-liter stainless steel bioreactors — the first and largest of their kind commissioned in China — providing an initial 80,000-liter drug substance capacity.
The facility's total planned capacity upon completion: 172,000 liters.
What makes this milestone particularly notable is the speed of achievement. Altruist secured the C Certificate just two months after facility qualification, an exceptionally rapid timeline for a complex biologics plant. The company attributes this to its proven quality management track record: 30 regulatory inspections passed to date, including audits by the FDA and EMA, plus 13 additional GMP quality audits from global pharmaceutical clients.
Altruist has already supported the commercialization of eight products, with several achieving regulatory submissions across the United States, Europe, and China. Its existing Suzhou site — with 60,000-liter capacity — meets NMPA, FDA, EMA, and PMDA standards.
The Hangzhou facility also houses a standalone ADC and AXC bioconjugation plant, supporting both small- and large-scale production of antibody-drug conjugates and other bioconjugates — a capability set that positions Altruist at the intersection of two of pharma's fastest-growing segments: biologics and ADCs.
The NMPA's April 2 notice — formally titled "Notice on Properly Carrying Out Segmented Production of Biologics" — represents the national rollout of a policy that had been operating under a limited pilot program since late 2024.
Under the previous regime, biologics manufacturers in China were effectively required to conduct all production steps — from cell culture through drug substance purification to final drug product fill-finish — within a single facility. This constraint, while simplifying regulatory oversight, forced companies to make massive upfront capital investments and limited their ability to leverage specialized capabilities across different sites.
The new policy removes this constraint, enabling:
Domestic segmented production: Different manufacturing steps (e.g., upstream drug substance vs. downstream drug product) can be conducted at separate facilities within China, provided the Marketing Authorization Holder (MAH) maintains an integrated quality assurance system covering all sites.
Cross-border segmented production: The policy explicitly accommodates scenarios where drug substance is manufactured overseas and imported into China for final drug product processing — or vice versa. Companies applying to add production scope to their Drug Production License can use regulatory documentation from overseas authorities in lieu of materials that would otherwise be inapplicable.
This aligns China's regulatory framework with established international practices in the United States, European Union, and Japan, where segmented manufacturing has long been standard for complex biologics.
The convergence of Altruist's scale milestone and NMPA's policy liberalization creates a multiplier effect for the bioprocessing supply chain:
Increased demand for single-use technology. Segmented manufacturing across multiple facilities drives adoption of single-use bioreactor systems, disposable filtration assemblies, and flexible tubing sets — reducing cross-contamination risk and enabling rapid changeover between products.
Chromatography resin consumption rises. Each additional manufacturing site requires dedicated purification capacity. Protein A resins, ion exchange media, and mixed-mode chromatography materials all see proportional demand increases as production fragments across sites.
Analytical instrumentation demand multiplies. Every facility operating under segmented manufacturing needs standalone analytical capability — HPLC, mass spectrometry, bioassay platforms, and environmental monitoring systems — rather than relying on centralized QC laboratories.
Cell culture media and feed supplements. The Hangzhou facility's four 20,000-liter bioreactors alone represent significant demand for high-quality cell culture media, growth factors, and feed supplements. As the facility scales to its planned 172,000-liter total capacity, consumption will increase proportionally.
Cold chain and logistics infrastructure. Cross-border segmented production creates demand for validated cold chain logistics, including temperature-controlled shipping for drug substance intermediates between manufacturing sites.
Altruist's entry into large-scale commercial manufacturing intensifies competition in China's CDMO market, which has been dominated by WuXi Biologics and Samsung Biologics' Chinese operations. WuXi currently operates 15 GMP-certified facilities globally with 136 facility license approvals, while Samsung Biologics runs the world's largest single-site biologics contract manufacturing facility in Incheon, South Korea.
However, the segmented manufacturing policy creates a more nuanced competitive landscape. Rather than a pure capacity race, the new framework enables specialization — facilities that excel at specific manufacturing steps (e.g., cell culture, purification, or fill-finish) can compete independently of total site capacity. This benefits niche suppliers of specialized bioprocessing equipment, single-use assemblies, and analytical services.
China's biologics manufacturing reforms extend beyond the NMPA's April 2 notice. The revised Implementing Regulations of the Drug Administration Law — effective May 15, 2026 — will provide the overarching legal framework for segmented production, including provisions for:
Marketing Authorization Holder (MAH) oversight obligations across all manufacturing sites
Integrated quality assurance system requirements
Supplier certification and change management protocols
Batch release responsibilities remaining with the MAH regardless of manufacturing site location
For bioprocessing suppliers and CDMOs, the message is clear: China's biologics manufacturing regulatory modernization is creating a larger, more fragmented, and more accessible market. Suppliers positioned with validated, globally compliant products and services will find growing demand not just from Chinese biopharma companies seeking to expand capacity, but from international clients leveraging China's newly flexible manufacturing framework for cost-effective, high-quality biologics production.
